1921
Volume 99, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Mucosal leishmaniasis (ML) is associated with progressive tissue destruction and granuloma formation, often after a considerable period of latency from an initial cutaneous infection. We report a case of recurrent epistaxis of 3 years duration and nasopharyngeal obstruction in a woman with treated cutaneous leishmaniasis nearly 30 years before and with no further exposure to Leishmania. Computed tomography revealed nasal septal perforation and histopathology demonstrated chronic inflammation. Microscopy was negative for amastigotes, but molecular testing of nasal mucosa biopsy detected . The patient underwent 28 days of treatment with IV sodium stibogluconate and her symptoms improved significantly. Sixteen months after treatment, she continues to have episodic epistaxis and detectable parasite load in her nasal lesion. Although ML is known to take years to decades to develop, there are few reported cases in the literature of such a long latency period. This report highlights the importance of considering ML in the differential diagnosis of chronic epistaxis in countries where leishmaniasis is endemic or in immigrants from these countries, even when presentation occurs decades after leaving an endemic region.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.17-0831
2018-06-04
2019-11-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/2/tpmd170831.html?itemId=/content/journals/10.4269/ajtmh.17-0831&mimeType=html&fmt=ahah

References

  1. Rojas-Jaimes J, , 2012. Leishmaniasis: una enfermedad desatendida. Un acercamiento a la realidad en Huepetuhe, Madre de Dios. Rev Peru Epidemiol 16: 14. [Google Scholar]
  2. Couto DV, Hans Filho G, Medeiros MZ, Vicari CFS, Barbosa AB, Takita LC, , 2014. American tegumentary leishmaniasis—a case of therapeutic challenge. An Bras Dermatol 89: 974976, doi: 10.1590/abd1806-4841.20143073. [Google Scholar]
  3. Ministerio De Salud, , 2015. Análisis y tendencias de la leishmaniasis en el Perú. Sala Situacional 1: 885–888. Available at: http://www.dge.gob.pe/portal/docs/vigilancia/boletines/2015/26.pdf. Accessed December 7, 2015.
  4. Savoia D, , 2015. Recent updates and perspectives on leishmaniasis. J Infect Dev Ctries 9: 588596. [Google Scholar]
  5. Oliveira-Neto M, Schubach A, Mattos M, Goncalves S, Pirmez C, , 1997. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil—an area of Leishmania (V.) braziliensis transmission. Int J Dermatol 36: 463468. [Google Scholar]
  6. Reveiz L, Maia-Elkhoury A, Santiago R, Sierra G, Yadon Z, , 2013. Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update. PLoS One 8: 114. [Google Scholar]
  7. Llanos-Cuentas A, Echevarría J, Cruz M, La Rosa A, Campos P, Campos M, Franke E, Berman J, Modabber F, Marr J, , 1997. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 25: 677684. [Google Scholar]
  8. Veland N, 2011. Polymerase chain reaction detection of leishmania kDNA from the urine of peruvian patients with cutaneous and mucocutaneous leishmaniasis. Am J Trop Med Hyg 84: 556561. [Google Scholar]
  9. Rojas-Cabrera E, Guzmán J, Verduguez A, , 2011. Leishmaniasis mucosa laríngea sin puerta de entrada evidente: presentación de un caso clínico. Gac Méd Boliv 34: 9193. [Google Scholar]
  10. Añez N, Rojas A, Crisante G, Jerez M, , 2012. Detección de Leishmania braziliensis en lesión mucosa con 16 años de evolución: registro de un caso. Bol Malariol Salud Ambient 52: 1529. [Google Scholar]
  11. Walton BC, Valverde Chinel L, Eguia Eguia YO, , 1973. Onset of espundia after many years of occult infection with Leishmania braziliensis. Am J Trop Med Hyg 22: 696698. [Google Scholar]
  12. Sáenz RE, Paz HM, de Rodriguez GC, de Vásquez AM, Mata RE, Johnson CM, , 1989. Mucocutaneous leishmaniasis in Panama: etiologic agent, epidemiologic and clinical aspects. Rev Med Panama 14: 615. [Google Scholar]
  13. Saenz E, Sialer M, Thomas E, Tejada E, Casanova E, , 2013. Leishmaniasis mucocutánea con presentación atípica: setenta años posprimoinfección. Dermatol PERU 23: 3742. [Google Scholar]
  14. Lessa MM, Lessa HA Castro TW Oliveira A Scherifer A Machado P Carvalho EM, 2007. Mucosal leishmaniasis: epidemiological and clinical aspects. Braz J Otorhinolaryngol 73: 843847. [Google Scholar]
  15. Scope A, Trau H, Bakon M, Yarom N, Nasereddin A, Schwartz E, , 2003. Imported mucosal leishmaniasis in a traveler. Clin Infect Dis 37: e837. [Google Scholar]
  16. Tirelli F, Roselino AM, Vernal S, , 2017. Final diagnosis of 86 cases included in differential diagnosis of American tegumentary leishmaniasis in a Brazilian sample: a retrospective cross-sectional study. An Bras Dermatol 92: 642648. [Google Scholar]
  17. Pope LE, Hobbs CG, , 2005. Epistaxis: an update on current management. Postgrad Med J 81: 309314. [Google Scholar]
  18. Cuba C, , 2000. Diagnostico parasitologico de la leishmaniasis tegumentaria Americana. Rev Med Exp 17: 14. [Google Scholar]
  19. Gomes CM, de Morais OO, Roselino AM, de Paula NA, Soares KA, Sampaio RNR, , 2014. Complementary exams in the diagnosis of American tegumentary leishmaniasis. An Bras Dermatol 89: 701709. [Google Scholar]
  20. De Oliveira-Neto MP, 2000. American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: main clinical and epidemiologic characteristics. Int J Dermatol 39: 506514. [Google Scholar]
  21. Andrade RV, Massone C, Lucena MN, Talhari AC, Talhari S, Guerra JA, Ferreira LC, , 2011. The use of polymerase chain reaction to confirm diagnosis in skin biopsies consistent with American tegumentary leishmaniasis at histopathology: a study of 90 cases. An Bras Dermatol 86: 892896. [Google Scholar]
  22. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S, , 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581596. [Google Scholar]
  23. Sadeghian G, Nilforoushzadeh MA, , 2006. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 45: 819821. [Google Scholar]
  24. Den Boer M, Argaw D, Jannin J, Alvar J, , 2011. Leishmaniasis impact and treatment access. Clin Microbiol Infect 17: 14711477. [Google Scholar]
  25. Sampaio SAP, Castro RM, Dillon NL, Martins JEC, , 1971. Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: a report of 70 cases. Int J Dermatol 10: 179181. [Google Scholar]
  26. Herwaldt BL, , 1999. Leishmaniasis. Lancet 354: 11911199. [Google Scholar]
  27. Croft SL, Olliaro P, , 2011. Leishmaniasis chemotherapy-challenges and opportunities. Clin Microbiol Infect 17: 14781483. [Google Scholar]
  28. Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B, , 2014. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Glob Health 2: e517. [Google Scholar]
  29. Soto J, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 12661272. [Google Scholar]
  30. Ojha R, Cervantes D, Fischbach L, , 2007. Oral pentoxifylline and pentavalent antimony for treatment of leishmaniasis: promising but Inconclusive evidence of superiority, compared with antimony monotherapy. Clin Infect Dis 45: 1104. [Google Scholar]
  31. Machado PR, Lessa H, Lessa M, Guimarães LH, Bang H, Ho JL, Carvalho EM, , 2007. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 44: 788793. [Google Scholar]
  32. Brito G, Dourado M, Polari L, Celestino D, Carvalho LP, Queiroz A, Carvalho EM, Machado PR, Passos S, , 2014. Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. Am J Trop Med Hyg 90: 617620. [Google Scholar]
  33. Lessa HA, Machado P, Lima F, Cruz AA, Bacellar O, Guerreiro J, Carvalho EM, , 2001. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 65: 879. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0831
Loading
/content/journals/10.4269/ajtmh.17-0831
Loading

Data & Media loading...

  • Received : 24 Oct 2017
  • Accepted : 13 Apr 2018
  • Published online : 04 Jun 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error